Clinical trials: CHD Risk-Equivalent Disease
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche
Coronary Disease
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)
This purpose of this study is to determine if the administration of ezetimibe and simvastatin together is more effective than simvastatin alone in lowering LDL-C levels to a goal of <100 mg/dL in patients at risk for Heart…
- Trial name
- NCT00551447
- Testing
- MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27 Weeks, Comparator: simvastatin / Duration of Treatment: 27 Weeks
- Volunteers
- 616 people
- Sponsor
- Organon and Co
Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)
This study will evaluate the efficacy of anacetrapib (100 mg) for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assess the safety and tolerability of anacetrapib (100 mg) in…
- Trial name
- DEFINE (NCT00685776)
- Testing
- anacetrapib
- Volunteers
- 1,623 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Coronary Heart Disease
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and…
- Trial name
- POLARIS (NCT00653588)
- Testing
- Rosuvastatin, Atorvastatin
- Sponsor
- AstraZeneca
Coronary Heart Disease
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
This 2 arm study will investigate the efficacy and safety of RO4607381 in patients with coronary heart disease, or CHD risk equivalent.
- Trial name
- NCT00353522
- Testing
- dalcetrapib
- Where
- 17 sites in United States, Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Coronary Heart Disease
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents.
- Trial name
- NCT00655538
- Testing
- dalcetrapib
- Where
- 23 sites in Austria, France and 5 more
- Volunteers
- 476 people
- Sponsor
- Hoffmann-La Roche